Chongqing Zhifei Biological Products Co Ltd: A Leader in Vaccine Development
Chongqing Zhifei Biological Products Co Ltd, a prominent player in the health care biotechnology sector, is headquartered in Chongqing, China. Established in 2001, the company has carved a niche for itself in the research, development, manufacture, and marketing of vaccines. Its product portfolio includes a range of vaccines aimed at preventing various infectious diseases, such as HibACon, MeningACon, and Menwayc, which are designed to combat meningococcal infections. Additionally, the company offers Vaccae for pulmonary tuberculosis treatment and vaccines for Haemophilus influenzae type b and hepatitis A.
The company’s commitment to public health is evident in its diverse range of vaccines, which address critical health concerns such as meningitis, pneumonia, sepsis, and tuberculosis. These products are crucial in preventing invasive diseases in infants and adults, showcasing Chongqing Zhifei’s role in global health initiatives.
Financially, Chongqing Zhifei Biological Products Co Ltd is listed on the Shenzhen Stock Exchange, with a market capitalization of 47.51 billion CNY as of April 27, 2025. The company’s stock closed at 19.21 CNY on the same date, reflecting a 52-week low, while its highest trading price in the past year was 40.43 CNY on October 8, 2024. The price-to-earnings ratio stands at 179.855, indicating the market’s valuation of the company’s earnings potential.
Since its initial public offering on September 28, 2010, Chongqing Zhifei has maintained a strong presence in the biotechnology industry, driven by its innovative vaccine solutions and strategic market positioning. For more information, the company’s website is available at www.zhifeishengwu.com .
In summary, Chongqing Zhifei Biological Products Co Ltd continues to be a key player in the biotechnology sector, with a focus on developing vaccines that address significant global health challenges. Its financial performance and product offerings underscore its commitment to advancing public health through innovative solutions.